Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Lewy body dementia

Topic: Risk, prevention and care in population studies

Plain-language summary

While sex differences were not apparent at asymptomatic stages, females showed more rapid declines across all outcomes in symptomatic stages compared to males. In asymptomatic participants, the association between baseline NfL and clinical trajectories was weaker in females versus males, a difference that was not present in symptomatic participants. In genetic FTD, females show cognitive resilience in early disease stages followed by steeper clinical declines later in the disease. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD-causing mutations. HIGHLIGHTS: Females with genetic FTD exhibit overall steeper increases in plasma neurofilament light chain (NfL) than males. Females with genetic FTD outperform NfL levels in asymptomatic stages compared to males. Once symptomatic, females with genetic FTD decline more rapidly than males. Plasma NfL is a stronger prognostic marker in asymptomatic males than females.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 337 participants. In genetic FTD, females showed cognitive resilience in early disease stages but steeper clinical declines once symptomatic compared to males. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD-causing mutations.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Memel, M., Staffaroni, A. M., Illán‐Gala, I., Castro, J. G., Kornak, J., Tartaglia, C. M., et al. (2025). Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14630

Vancouver

Memel M, Staffaroni AM, Illán‐Gala I, Castro JG, Kornak J, Tartaglia CM, et al. Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14630. PMID: 40277077.

BibTeX

@article{memel2025-40277077,
  author  = {Memel, Molly and Staffaroni, Adam M. and Illán‐Gala, Ignacio and Castro, Jesús García and Kornak, John and Tartaglia, Carmela M. and Saloner, Rowan and VandeBunte, Anna M. and others},
  title   = {{Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14630},
  pmid    = {40277077},
  url     = {https://doi.org/10.1002/alz.14630}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In genetic FTD, females showed cognitive resilience in early disease stages but steeper clinical declines once symptomatic compared to males. Baseline NfL may be a less sensitive prognostic tool for clinical progression in females with FTD-causing mutations.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 337 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 15 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 9.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Kaitlin Blackstone Casaletto: h-index 42 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 22 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40277077)
Free to read 2 / 2 Free to read
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Lewy body dementia from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →